Trial Profile
A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms verITI-8 Study
- Sponsors Bioverativ
- 03 Feb 2023 Final Results of the verITI-8 Study published in the Blood
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 18 Mar 2021 Status changed from active, no longer recruiting to completed.